Detailed narrative
Agent 797 Mechanism and Strategic Importance
Agent 797 is an allogeneic, off-the-shelf invariant natural killer T cell product designed to address uncontrolled infection, dysregulated inflammation, and impaired tissue repair in critical illness. Its unique non-polymorphic CD1D restriction allows for broad use without HLA matching or graft-versus-host risk, making it practical for rapid deployment. This combination of potent biologic activity and practical deployability is central to MiNK's strategy to transform cell therapy from a complex intervention to a readily available treatment.
C1300O2 Study Initiation and Early Observations
The randomized Phase 2 study (C1300O2) of Agent 797 in acute lung injury and ARDS was initiated in Lviv, Ukraine, in collaboration with Unbroken Ukraine. Initial observations from the first two treated patients, including a 41-year-old female with poorly controlled diabetes and pneumococcal sepsis, showed survival without fever at day 28, improved oxygenation, resolution of ARDS, and liberation from vasopressor support. Microbiologic findings indicated control of baseline infection, and no major serious adverse events were attributed to Agent 797. These early, non-comparative results are considered provocative but require confirmation through the randomized portion of the study.
International Paid Patient Access Program Launch
MiNK launched its first international paid named patient access program in Brazil, in collaboration with Orphan Drug Consultants. This program enables treating physicians to request Agent 797 for individual patients with serious unmet needs, subject to case-by-case regulatory authorization. It is a paid program, providing MiNK with payment for products supplied on a per-patient basis, and establishes critical operational infrastructure for cross-border delivery of off-the-shelf cell therapy, a capability often lacking in cell therapy programs.
Translational and Clinical Evidence Supporting Agent 797
The company highlighted a growing body of evidence supporting Agent 797's broad potential. This includes evidence of pathogen suppression and lung immune restoration in severe fungal infection (ATS conference), context-dependent immune responses (ASGCT) where it showed immune activation in cancer and inflammation regulation in ARDS, and mechanistic insights into INKT cell depletion in advanced pulmonary fibrosis (Keystone Symposium). Additionally, Phase 2 data in PD-1 refractory gastroesophageal cancer showed a 77% disease control rate and durable survival in a subset of patients.
Financial Discipline and Non-Dilutive Funding Strategy
Despite an increase in cash used in operations to $2.1 million for Q2 FY26, reflecting the launch costs of the randomized Phase 2 study, MiNK maintains stringent financial discipline. The company emphasizes a lean infrastructure and headcount, and prioritizes non-dilutive funding, with the graft-versus-host disease trial at University of Wisconsin and a pediatric program being externally funded. The paid patient access program also contributes resource support for ongoing clinical trials.
Broader Opportunity and Future Priorities
MiNK aims to leverage Agent 797 to restore coordinated immune function across various conditions, including critical illness, trauma, transplantation, cancer, and fibrotic diseases. The company's key priorities include continuing enrollment in the C1300O2 study, activating US sites, expanding the comparative clinical and biologic data set, and responsibly executing the named patient program. The goal is to generate evidence to confirm Agent 797's ability to meaningfully change patient outcomes.